[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536851":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":37,"centralContacts":42,"locations":51,"responsibleParty":133,"collaborators":30,"id":135,"slug":136,"hasResults":137,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":30,"eligibilityCriteria":141,"healthyVolunteers":137,"sex":142,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":30,"studyType":148,"phases":149,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":54,"whyStopped":30,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},{"fullName":5,"class":6},"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","ACTIVE_COMPARATOR","Standard cell therapy (control group)",[13],"Biological: Control",{"label":15,"type":16,"description":17,"interventionNames":18},"Allogenic fetal mesenchymal stem cells from umbilical cord - three infusions","EXPERIMENTAL","Treatment: three infusions of MSC 5x10\\^6\u002FKg",[19],"Biological: Allogenic fetal mesenchymal stem cells from umbilical cord - three infusions",{"label":21,"type":16,"description":22,"interventionNames":23},"Allogenic fetal mesenchymal stem cells from umbilical cord - six infusions","Treatment: six infusions of MSC 5x10\\^6\u002FKg",[24],"Biological: Allogenic fetal mesenchymal stem cells from umbilical cord - six infusions",[26,31,34],{"type":27,"name":9,"description":28,"armGroupLabels":29,"otherNames":30},"BIOLOGICAL","Standard treatment",[9],null,{"type":27,"name":15,"description":32,"armGroupLabels":33,"otherNames":30},"3 doses of 5 million MSC will be administered",[15],{"type":27,"name":21,"description":35,"armGroupLabels":36,"otherNames":30},"6 doses of 5 million MSC will be administered",[21],[38],{"name":39,"affiliation":40,"role":41},"María Jesús del Cerro, PhD","IRYCIS. Hospital Universitario Ramón y Cajal. Madrid, Spain.","PRINCIPAL_INVESTIGATOR",[43,47],{"name":39,"role":44,"phone":45,"phoneExt":30,"email":46},"CONTACT","34 91 36 8000","majecerro@yahoo.es",{"name":48,"role":44,"phone":49,"phoneExt":30,"email":50},"María Álvarez, MD","34 9 336 8000","mery1812@hotmail.com",[52,69,80,90,98,109,122],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Hospital Quironsalud Madrid","RECRUITING","Pozuelo de Alarcón","Madrid","28223","Spain","ES",{"type":61,"coordinates":62},"Point",[63,64],-3.81338,40.43293,{"lat":64,"lon":63},[67],{"name":68,"role":44,"phone":30,"phoneExt":30,"email":30},"Fernando Cabañas",{"facility":70,"status":54,"city":71,"state":30,"zip":30,"country":58,"countryCode":59,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Complejo Hospitalario La Coruña","A Coruña",{"type":61,"coordinates":73},[74,75],-8.396,43.37135,{"lat":75,"lon":74},[78],{"name":79,"role":44,"phone":30,"phoneExt":30,"email":30},"Alejandro Dávila",{"facility":81,"status":54,"city":56,"state":30,"zip":30,"country":58,"countryCode":59,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Hospital Clínico San Carlos",{"type":61,"coordinates":83},[84,85],-3.70256,40.4165,{"lat":85,"lon":84},[88],{"name":89,"role":44,"phone":30,"phoneExt":30,"email":30},"Luis Arruza",{"facility":91,"status":54,"city":56,"state":30,"zip":30,"country":58,"countryCode":59,"cosmosGeoPoint":92,"geoPoint":94,"contacts":95},"Hospital Universitario La Paz",{"type":61,"coordinates":93},[84,85],{"lat":85,"lon":84},[96],{"name":97,"role":44,"phone":30,"phoneExt":30,"email":30},"Paloma Lopez",{"facility":99,"status":54,"city":100,"state":30,"zip":30,"country":58,"countryCode":59,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Hospital Universitario Carlos Haya","Málaga",{"type":61,"coordinates":102},[103,104],-4.42034,36.72016,{"lat":104,"lon":103},[107],{"name":108,"role":44,"phone":30,"phoneExt":30,"email":30},"Tomás Sánchez Tamayo",{"facility":110,"status":54,"city":111,"state":30,"zip":30,"country":58,"countryCode":59,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Hospital Vírgen del Rocío","Seville",{"type":61,"coordinates":113},[114,115],-5.97317,37.38283,{"lat":115,"lon":114},[118,120],{"name":119,"role":44,"phone":30,"phoneExt":30,"email":30},"Antonio Pavón Delgado",{"name":121,"role":41,"phone":30,"phoneExt":30,"email":30},"María José Moreno Valera",{"facility":123,"status":54,"city":124,"state":30,"zip":30,"country":58,"countryCode":59,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Hospital Universitario y Politécnico La Fe","Valencia",{"type":61,"coordinates":126},[127,128],-0.37966,39.47391,{"lat":128,"lon":127},[131],{"name":132,"role":44,"phone":30,"phoneExt":30,"email":30},"Máximo Vento",{"type":134,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100536851","phase-2-use-of-mesenchymal-stem-cells-in-pre-term-patients-with-bronchopulmonary-dysplasia-100536851",false,"NCT06270199","Use of Mesenchymal Stem Cells in Pre-term Patients With Bronchopulmonary Dysplasia.","Clinical Trial to Stablish the Security of Using Allogeneic Fetal Stem Mesenchymal Cells From Umbilical Cord, Expanded in Pre-term Patients Suffering of Bronchopulmonary Dysplasia.","Inclusion Criteria:\n\n* Alive newborns weighing ≤ 1250 grams and GA ≤ 28 weeks, who are on mechanical ventilation with a FiO2 ≥0.3 between days 5 and 14 of life, with no immediate extubation foreseeable.\n\nExclusion Criteria:\n\n* Presence of another concomitant congenital pathology at the time of inclusion: pulmonary malformations with compromised pulmonary function, active pulmonary haemorrhage, severe pulmonary hypoplasia, renal malformations with systemic compromise, congenital heart disease, polymalformative syndromes, chromosomopathies.\n* Presence of refractory haemodynamic instability of any cause at the time of inclusion.\n* Presence of severe neurological damage at the time of inclusion (HIV grade III or higher).\n* Patients who have required major surgery in the 72 hours prior to inclusion.\n* Patients who have necrotising enterocolitis (NEC) grades ≥II at the time of inclusion, according to the Bell classification.\n* Patients who are children of a mother with HIV","ALL","1 Month","28 Weeks",{"count":146,"type":147},75,"ESTIMATED","INTERVENTIONAL",[150],"PHASE2","Bronchopulmonary dysplasia (BPD) is a disease that affects preterm newborn patients, preventing their lungs from developing properly. Allogeneic fetal stem mesenchymal cells from umbilical cord could reduce the prevalence of BPD in this patients.",[153],"Bronchopulmonary Dysplasia",[155,156,157],"Bronchopulmonary dysplasia","Preterm newbnorn","Mesenchymal stem cells","2025-03-14",{"date":160,"type":161},"2025-03-17","ACTUAL",{"date":163,"type":161},"2024-01-11",{"date":165,"type":147},"2026-12",{"name":5,"class":6},7]